Education
About Us
Working with TipRanks
Follow Us
ImageneBio (IMA)
NASDAQ:IMA
IMA Stock Chart & Stats
$6.47
--
Market closed
$6.47
--
Day’s Range― - ―
52-Week Range$6.19 - $23.28
Previous CloseN/A
VolumeN/A
Average Volume (3M)69.52K
Market Cap
$92.14M
Enterprise Value-$25.30M
Total Cash (Recent Filing)$142.58M
Total Debt (Recent Filing)$10.96M
Price to Earnings (P/E)―
Beta0.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,181,676
10 Day Avg. Volume58,561
30 Day Avg. Volume69,515
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)7.54
Price to Sales (P/S)0.00
P/FCF Ratio-20.64
Enterprise Value/Market Cap-0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.03
Enterprise Value/Ebitda0.46
Forecast
1Y Price Target
$16.00Price Target Upside147.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FundingThe company completed a $75.0 million private funding following the reverse merger.
LeadershipCEO Kristin Yarema brings over two decades of biopharma leadership experience, optimizing the company's strategy, management, and execution.
Product DifferentiationIMG-007 has the potential to differentiate on safety given its non-T-cell–depleting design, while still achieving high efficacy by targeting OX40 rather than OX40L.
Bears Say
CompetitionCompetition is strong, with other companies advancing candidates that are either equivalent or superior.
Financial PositionThere is concern about the company’s financial position, which leaves little buffer for clinical trial delays and will likely require substantial dilution to advance forward.
Market EntryLate entry into the atopic dermatitis market with limited prospects for monotherapy success due to competition.
ImageneBio News
IMA FAQ
What was ImageneBio’s price range in the past 12 months?
ImageneBio lowest stock price was $6.19 and its highest was $23.28 in the past 12 months.
What is ImageneBio’s market cap?
ImageneBio’s market cap is $92.14M.
When is ImageneBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImageneBio’s earnings last quarter?
ImageneBio released its earnings results on Aug 07, 2025. The company reported -$0.688 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.358.
Is ImageneBio overvalued?
According to Wall Street analysts ImageneBio’s price is currently Undervalued.
Does ImageneBio pay dividends?
ImageneBio does not currently pay dividends.
What is ImageneBio’s EPS estimate?
ImageneBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImageneBio have?
ImageneBio has 11,181,676 shares outstanding.
What happened to ImageneBio’s price movement after its last earnings report?
ImageneBio reported an EPS of -$0.688 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went down -0.697%.
Which hedge fund is a major shareholder of ImageneBio?
Currently, no hedge funds are holding shares in IMA
ImageneBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (147.30% Upside)
$16.00 (147.30% Upside)
Hedge Fund Trend
Increased
By 267.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.25%
12-Months-Change
Fundamentals
Return on Equity
-33.05%
Trailing 12-Months
Asset Growth
-19.89%
Trailing 12-Months
Company Description
ImageneBio
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
IMA Stock 12 Month Forecast
Average Price Target
$16.00
▲(147.30% Upside)
Technical Analysis
Ownership Overview
30.26% Insiders
1.63% Mutual Funds
37.24% Other Institutional Investors
28.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---